MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Anika Therapeutics DSO Ratio 2011-2026 | ANIK
Annual DSO Ratio Anika Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.3 | 75.3 | 66.6 | 66 | 73.5 | 71.8 | 76.7 | 97.4 | 85 | 59.3 | 91.1 | 110 | 97.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 | 59.3 | 80.6 |
Quarterly DSO Ratio Anika Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.7 | 74.3 | 79.5 | - | 95.9 | 97.8 | 107 | - | - | 69.4 | 36.9 | - | - | - | 37.1 | - | 71.3 | 66.9 | 67.3 | 67.3 | 69.4 | 71.7 | 60.8 | 70.7 | 70.9 | 69.2 | 80.9 | 70.3 | 70.8 | 62.1 | 95.7 | 74 | 80 | 65 | 100 | 87.7 | 97.7 | 94.7 | 101 | 64 | 83.4 | 86.3 | 114 | 67.3 | 71 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120 | 86.6 | 133 | 99.8 | 123 | 85.6 | 85.6 | 97.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 133 | 36.9 | 80.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M |  USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.88 | -2.07 % | $ 6.47 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.91 | 0.34 % | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.79 | 1.28 % | $ 27.9 M | Israel |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
87.4 | - | - | $ 35.4 M | USA |
 |
BioXcel Therapeutics
BTAI
|
103 | $ 1.06 | -2.75 % | $ 12.9 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |